<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Weintraub, Daniel</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">MODERATO Study to Assess the Effect of Rasagiline on Patients With Parkinson Disease and Mild Cognitive Impairment</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-20 11:31:42</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">9-9</style></pages><abstract><style  face="normal" font="default" size="100%">Parkinson disease (PD) with mild cognitive impairment (PD-MCI) is relatively common in nondemented PD patients, but currently there is no approved treatment. The phase 4 MODERATO is evaluating the effect of 24 weeks of treatment with rasagiline 1 mg/d as add-on therapy in adults with PD-MCI. The trial, which has enrolled 170 patients, is the largest to date to evaluate a treatment for PC-MCI.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>